journal article·2025-02Open access

TEAD1‐Mediated Trans‐Differentiation of Vascular Smooth Muscle Cells into Fibroblast‐Like Cells Contributes to the Stabilization and Repair of Disrupted Atherosclerotic Plaques

Ming Zhai, Zhijun Lei, Yefei Shi, Jiayun Shi, Yanxi Zeng, Shiyu Gong, Weixia Jian, Jianhui Zhuang, Qing Yu, Mark W. Feinberg, Wenhui Peng

Advanced Science· Volume 12· Issue 5

Abstract

Abstract Atherosclerotic plaque rupture mainly contributes to acute coronary syndrome (ACS). Insufficient repair of these plaques leads to thrombosis and subsequent ACS. Central to this process is the modulation of vascular smooth muscle cells (VSMCs) phenotypes, emphasizing their pivotal role in atherosclerotic plaque stability and healing post‐disruption. Here, an expansion of FSP1+ cells in a tandem stenosis (TS) model of atherosclerotic mice is unveiled, predominantly originating from VSMCs through single‐cell RNA sequencing (scRNA‐seq) analyses and VSMC lineage tracing studies. Further investigation identified TEA domain transcription factor 1 (TEAD1) as the key transcription factor driving the trans‐differentiation of VSMCs into fibroblast‐like cells. In vivo experiments using a TS model of plaque rupture demonstrated that TEAD1 played a crucial role in promoting plaque stability and healing post‐rupture through pharmacological or TEAD1‐AAV treatments. Mechanistically, it is found that TEAD1 promoted the expression of fibroblast markers through the Wnt4/β‐Catenin pathway, facilitating the trans‐differentiation. Thus, this study illustrated that TEAD1 played a critical role in promoting the trans‐differentiation of VSMCs into fibroblast‐like cells and subsequent extracellular matrix production through the Wnt4/β‐Catenin pathway. Consequently, this process enhanced the healing mechanisms following plaque rupture, elucidating potential therapeutic avenues for managing atherosclerotic instability.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Coronary Interventions and Diagnostics · Atherosclerosis and Cardiovascular Diseases · Cardiac Fibrosis and Remodeling

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Cardiology School of Medicine Shanghai Tenth People's Hospital Tongji University Shanghai 200072 China

Department of Endocrinology School of Medicine Xinhua Hospital Shanghai Jiaotong University Shanghai 200092 China

Cardiovascular Division Department of Medicine Brigham and Women's Hospital Harvard Medical School Boston MA 02115 USA

Funding

National Natural Science Foundation of China

References (57)

Show source-provided references
1. 10.1016/j.jacc.2019.08.01210.1016/j.jacc.2019.08.012 ↗
2. 10.1001/jamacardio.2022.392610.1001/jamacardio.2022.3926 ↗
3. 10.1038/s41569-022-00769-810.1038/s41569-022-00769-8 ↗
4. 10.1016/j.jcmg.2021.09.00810.1016/j.jcmg.2021.09.008 ↗
5. 10.1093/eurheartj/ehy41910.1093/eurheartj/ehy419 ↗
6. 10.3389/fimmu.2022.91512610.3389/fimmu.2022.915126 ↗
7. 10.1038/s41569-022-00687-910.1038/s41569-022-00687-9 ↗
8. Wang X. · N. Engl. J. Med. · 2021 · 384 · 293
9. 10.1001/jamacardio.2019.027510.1001/jamacardio.2019.0275 ↗
10. 10.3390/jcdd603002610.3390/jcdd6030026 ↗
11. 10.1016/j.pharmthera.2022.10823710.1016/j.pharmthera.2022.108237 ↗
12. 10.1056/NEJMra200031710.1056/NEJMra2000317 ↗
13. 10.1038/nm.386610.1038/nm.3866 ↗
14. 10.1074/jbc.M41286220010.1074/jbc.M412862200 ↗
15. 10.1006/jmcc.2002.208610.1006/jmcc.2002.2086 ↗
16. 10.1124/pr.115.01065210.1124/pr.115.010652 ↗
17. 10.1038/s41467-022-35330-110.1038/s41467-022-35330-1 ↗
18. 10.1161/CIRCULATIONAHA.120.04837810.1161/CIRCULATIONAHA.120.048378 ↗
19. 10.1161/CIRCULATIONAHA.120.04992210.1161/CIRCULATIONAHA.120.049922 ↗
20. 10.1161/CIRCRESAHA.115.30636110.1161/CIRCRESAHA.115.306361 ↗
21. 10.1093/cvr/cvs11510.1093/cvr/cvs115 ↗
22. 10.1016/j.atherosclerosis.2017.10.01110.1016/j.atherosclerosis.2017.10.011 ↗
23. 10.1161/ATVBAHA.116.30801710.1161/ATVBAHA.116.308017 ↗
24. 10.3389/fcvm.2021.75152510.3389/fcvm.2021.751525 ↗
25. 10.2119/molmed.2011.0047910.2119/molmed.2011.00479 ↗
26. 10.1093/cvr/cvad01610.1093/cvr/cvad016 ↗
27. 10.1038/s41591-019-0512-510.1038/s41591-019-0512-5 ↗
28. 10.1038/ncomms1185310.1038/ncomms11853 ↗
29. 10.1093/cvr/cvy02210.1093/cvr/cvy022 ↗
30. 10.1093/eurheartj/ehy12410.1093/eurheartj/ehy124 ↗
31. 10.1093/eurheartj/ehab92010.1093/eurheartj/ehab920 ↗
32. 10.1172/jci.insight.17463910.1172/jci.insight.174639 ↗
33. 10.1161/01.CIR.103.7.93410.1161/01.CIR.103.7.934 ↗
34. 10.1111/bph.1570110.1111/bph.15701 ↗
35. 10.1161/ATVBAHA.120.31516410.1161/ATVBAHA.120.315164 ↗
36. Myers P. R. · J. Lab. Clin. Med. · 1994 · 124 · 672
37. 10.1016/j.celrep.2022.11079210.1016/j.celrep.2022.110792 ↗
38. 10.1038/ncb321610.1038/ncb3216 ↗
39. 10.1038/s42255-022-00584-y10.1038/s42255-022-00584-y ↗
40. 10.1111/bph.1535610.1111/bph.15356 ↗
41. 10.4244/EIJ-D-18-0117510.4244/EIJ-D-18-01175 ↗
42. 10.1038/s41569-019-0169-210.1038/s41569-019-0169-2 ↗
43. 10.1161/CIRCRESAHA.120.31593510.1161/CIRCRESAHA.120.315935 ↗
44. 10.1002/stem.125610.1002/stem.1256 ↗
45. 10.1016/j.stem.2019.11.01010.1016/j.stem.2019.11.010 ↗
46. 10.1161/CIRCRESAHA.118.31418710.1161/CIRCRESAHA.118.314187 ↗
47. 10.1038/s41418-019-0335-410.1038/s41418-019-0335-4 ↗
48. 10.1038/s41467-017-00840-w10.1038/s41467-017-00840-w ↗
49. 10.1007/s12013-020-00952-z10.1007/s12013-020-00952-z ↗
50. Corrado D. · N. Engl. J. Med. · 2021 · 384 · 292
51. 10.1186/s10020-023-00685-810.1186/s10020-023-00685-8 ↗
52. 10.1016/j.stem.2020.02.01310.1016/j.stem.2020.02.013 ↗
53. 10.1016/j.mehy.2007.07.03110.1016/j.mehy.2007.07.031 ↗
54. 10.1161/CIRCRESAHA.122.32241810.1161/CIRCRESAHA.122.322418 ↗
55. 10.1111/bph.1535610.1111/bph.15356 ↗
56. 10.1016/S0021-9150(98)00133-610.1016/S0021-9150(98)00133-6 ↗
57. 10.1038/nmeth.446310.1038/nmeth.4463 ↗